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I GENERAL INTRODUCTION 
Depression is one of the most common psychiatric disorders and the leading cause of disability 
worldwide. According to the World Health Organization (WHO), more than 350 million 
individuals of all ages suffer from depression. 
Several clinical studies demonstrate that addition of low doses of atypical antipsychotic drugs 
(e.g., aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) to selective serotonin 
reuptake inhibitors (SSRIs) to rapidly enhance the antidepressant effects in patients with major 
depressive disorder (MDD), including treatment-resistant. Brexpiprazole (7-{4-[4-(1-
benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one), a serotonin-dopamine 
activity modulator, binds with high affinity (Ki < 1 nM) to human serotonin (5-HT) 5-HT1A, 
5-HT2A-, dopamine D2 (D2L)- and adrenergic α1B-, α2C-receptors. It displays partial 
agonism at 5-HT1A and D2 receptors, and potent antagonism of 5-HT2A receptors and 
α1B/2C-adrenoceptors . Furthermore, brexpiprazole could potentiate nerve growth factor-
induced neurite outgrowth in PC12 cells via 5-HT1A and 5-HT2A receptors. Moreover, 
brexpiprazole showed antipsychotic-like and pro-cognitive effects in rodents. Phase 3 
randomized, placebo-controlled studies demonstrated that brexpiprazole has beneficial effects 
in patients with inadequate response to antidepressants. Brexpiprazole has shown efficacy as 
adjunctive treatment of MDD. But the precise mechanisms underlying antidepressant effect are 
still unknown. 
This study, therefore, consists of two parts: I. To determine whether adjunctive treatment of 
brexpiprazole with fluoxetine shows a rapid antidepressant effect in a social defeat stress model; 
II. To determine whether combination of brexpiprazole and fluoxetine could show 
antidepressant effects on depression like behavior and dendritic changes in mice after 
inflammation.  
 
	 4	
II CHAPTER Ⅰ 
 
Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid 
antidepressant effect in a social defeat stress model: Role of BDNF-TrkB 
signaling  
1. Background  
Substantial clinical data demonstrate that addition of low doses of atypical antipsychotic drugs 
(e.g., aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) to selective serotonin 
reuptake inhibitors (SSRIs) rapidly enhance the antidepressant effects in patients with major 
depressive disorder (MDD), including treatment-resistant patients (Barbee et al, 2004; Brunner 
et al, 2014; Nelson and Papakostas, 2009; Papakostas et al, 2005; 2007; 2015; Shelton et al, 
2008). Although clinical outcome of combined atypical antipsychotic drug and SSRI might be 
similar to ketamine’s induced rapid antidepressant effect (Abdallah et al, 2015; Machado-Viera 
et al, 2016; Newport et al, 2015; Kishimoto et al, 2016), the precise mechanisms underlying 
rapid antidepressant effect of the combination are currently unclear (Blier, 2014; Rogóz, 2013). 
Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-
one) is a novel serotonin-dopamine activity modulator (Maeda et al, 2014a). Brexpiprazole 
binds with high affinity (Ki < 1 nM) to human serotonin (5-HT1A)-, 5-HT2A-, dopamine D2 
(D2L)-, α1B-, and α2C-adrenergic receptors. It displays partial agonism at 5-HT1A and D2 
receptors, and potent antagonism of 5-HT2A receptors and α1B/2C-adrenoceptors (Maeda et al, 
2014a). Furthermore, brexpiprazole could potentiate nerve growth factor (NGF)-induced 
neurite outgrowth in PC12 cells via 5-HT1A and 5-HT2A receptors (Ishima et al, 2015), 
suggesting that brexpiprazole can stimulate neuronal plasticity. Moreover, brexpiprazole 
showed antipsychotic-like and precognitive effects in rodents (Maeda et al, 2014b; Yoshimi et 
al, 2014; 2015). Brexpiprazole has been developed to offer efficacious and tolerable therapy 
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for schizophrenia (Citrome, 2015; Citrome et al, 2015; Correll et al, 2015; Das et al, 2016; 
Kane et al, 2015). In addition, brexpiprazole has been developed as adjunctive treatment of 
MDD (Citrome, 2015; Das et al, 2016; McKeage, 2016; Rogóz, 2013; Stahl, 2016; Thase et al, 
2015a; 2015b).  
The purpose of this study is to examine whether brexpiprazole could augment 
antidepressant-like effects of the SSRI fluoxetine in depression-like behaviors and alterations 
in the spine density in susceptible mice after repeated social defeat stress. It is well known that 
brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling plays a key role in 
the therapeutic mechanisms of the rapid antidepressants (Neslter et al, 2002; Hashimoto, 2010; 
2013; Hashimoto et al, 2004; Duman and Monteggia, 2006; Castrén, 2014; Zhang et al, 2016). 
Therefore, we examined the role of BDNF-TrkB signaling in the mechanisms of a rapid 
antidepressant action of combination of brexpiprazole and fluoxetine.  
2. Material and methods 
Animals 
Male adult C57BL/6 mice (8 weeks old) weighing 20–25 g and male adult CD1 mice aged 13–
15 weeks (body weight >40 g) were purchased from SLC Japan (Hamamatsu, Shizuoka, Japan). 
The mice were housed in clear polycarbonate cages (22.5 × 33.8 × 14.0 cm) in groups of 4 or 
5 individuals under a controlled 12/12-h light–dark cycle (light from 7:00 AM to 7:00 PM), 
with the room temperature kept at 23 ± 1°C and humidity at 55 ± 5%. The mice were given 
free access to water and food pellets specifically designed for mice. The experimental 
procedure was approved by the Animal Care and Use Committee of Chiba University Graduate 
School of Medicine. 
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Drugs and drug administration 
Brexpiprazile was synthesized at Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Vehicle (0.5% 
CMC; 10 ml/kg), fluoxetine (10 mg/kg, Wako Chemical Co., Ltd, Tokyo, Japan), 
brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) were 
administered orally into mice. To study the role of BDNF-TrkB signaling in the mechanism of 
fluoxetine plus brexpiprazole, vehicle (17% dimethyl sulfoxide (DMSO) in phosphate-
buffered saline) or ANA-12 (N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl) amino] carbonyl] 
phenyl]-benzo[b]thiophene-2-carboxamide; 0.5 mg/kg, Maybridge, Loughborough, 
Leicestershire, UK)) was administrated intraperitoneally (i.p.) into mice. The doses of 
brexpiprazole (0.1 mg/kg), fluoxetine (10 mg/kg) and ANA-12 (0.5 mg/kg) were selected as 
reported previously (Cazorla et al, 2011; Maeda et al, 2014a; 2014b; Ren et al, 2014; 2015; 
Rogóz, 2013; Yoshimi et al, 2015; Zhang et al, 2015a; 2015b). Other chemicals were 
purchased from commercial sources. 
Social defeat procedure 
The procedure of social defeat stress was performed as previously reported (Berton et al, 2006; 
Golden et al, 2011; Ren et al, 2015; 2016; Yang et al, 2015b; Zhang et al, 2015a; 2015b). 
Every day the C57BL/6 mice were exposed to a different CD1 aggressor mouse for 10 min, 
total for 10 days. When the social defeat session ended, the resident CD1 mouse and the 
intruder mouse were housed in one half of the cage separated by a perforated Plexiglas divider 
to allow visual, olfactory and auditory contact for the remainder of the 24- h period. At 24 h 
after the last session, all mice were housed individually. On day 11, a social avoidance test was 
performed to identify subgroups of mice that were susceptible and unsusceptible to social 
defeat stress. This was accomplished by placing mice in an interaction test box (42 × 42 cm) 
with an empty wire-mesh cage (10 × 4.5 cm) located at one end. The movement of the mice 
was tracked for 2.5 min, followed by 2.5 min in the presence of an unfamiliar aggressor 
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confined in the wire-mesh cage. The duration of the subject’s presence in the 'interaction zone' 
(defined as the 8-cm-wide area surrounding the wire-mesh cage) was recorded by a stopwatch. 
The interaction ratio was calculated as the time spent in an interaction zone with an 
aggressor/time spent in an interaction zone without an aggressor. An interaction ratio of 1 was 
set as the cutoff: mice with scores <1 were defined as 'susceptible' to social defeat stress and 
those with scores ≥1 were defined as 'unsusceptible'. Only susceptible mice were used in the 
subsequent experiments.  
Behavioral tests of antidepressant effects 
Behavioral tests were performed as previously reported (Ren et al, 2015; 2016; Yang et al, 
2015b; Zhang et al, 2015a; 2015b). 
Locomotion: Mice were placed in experimental cages (L560×W560×H330 mm), and 
locomotor activity was counted by the SCANET MV-40 (MELQUEST, Toyama, Japan). The 
cumulative exercise was recorded for 60 min. All cages were cleaned between testing session. 
Tail suspension test: The tail of mice was tapped by a small piece of adhesive tape. The place 
is 2 cm from the tip of the tail. A single hole was punched in the tape and mice were hung 
individually, on a hook. The immobility time of each mouse was recorded for 10min. Mice 
were considered immobile only when they hung passively and completely motionless. 
Force swimming test: Animals were tested in an automated forced-swim apparatus using 
SCANET MV-40 (MELQUEST Co., Ltd., Toyama, Japan). The mice were placed individually 
in a cylinder (Deep 23cm; Height 21cm), containing 15 cm of water, kept/maintained at 23 ± 
1°C. Immobility time was calculated from activity time as (total) − (active) time, using the 
apparatus analysis software. Cumulative immobility time was scored for 6 min during the test. 
The TST and FST were also performed 2 and 4 h after the LMT, respectively. 
Sucrose preference test: Mice were exposed to water and 1% sucrose solution for 48 h, 
followed by 4 h of water and food deprivation and a 1-h exposure to two identical bottles: one 
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of water and another of 1% sucrose solution. The bottles containing water and sucrose were 
weighed before and at the end of this period and the sucrose preference (%) was determined 
Western blot analysis of BDNF, and its precursor proBDNF, TrkB, and phosphorylated-
TrkB  
Western blot analysis was performed as reported previously (Ren et al, 2015; 2016; Yang et 
al, 2015b; Zhang et al, 2015a; 2015b). Mice were killed by cervical dislocation and brains were 
rapidly removed from the skull. Approximately 1-mm-thick coronal sections were cut and 
bilateral tissue punches of prefrontal cortex (PFC), nucleus accumbens (NAc), striatum, CA1, 
CA3, and dentate gyrus (DG) of the hippocampus were dissected on ice using a SZ-LED Kenis 
light microscope (Osaka, Japan), and stored at −80°C. Basically, tissue samples were 
homogenized in Laemmli lysis buffer. Aliquots (20 µg) of protein were measured using the 
DC protein assay kit (Bio-Rad), and incubated for 5 min at 95°C, with an equal volume of 125 
mM Tris-HCl, pH 6.8, 20% glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol, 4% 
SDS, and subjected to SDS polyacrylamide gel electrophoresis using AnyKD minigels (Mini-
PROTEAN TGX Precast Gel; BioRad). Proteins were transferred onto PVDF membranes 
using a Trans Blot Mini Cell (Bio-Rad). For immunodetection, the blots were blocked with 2% 
BSA in TBST (TBS + 0.1% Tween-20) for 1 h at room temperature, and kept with primary 
antibodies overnight at 4°C. The following primary antibodies were used: BDNF (1:200; H-
117, Cat#: sc-20981, Santa Cruz Biotechnology), phosphor-TrkB (Tyr-706) (1:200; Cat#: 
sc135645, Santa Cruz Biotechnology), TrkB (80E3) (1:1,000; Cat#: 4603, Cell Signaling 
Technology). The next day, blots were washed three times in TBST, and incubated with 
horseradish peroxidase-conjugated anti-rabbit antibody (1:10,000) 1 hour at room temperature. 
After a final three washes with TBST, bands were detected using enhanced chemiluminescence 
(ECL) plus the Western Blotting Detection system (GE Healthcare Bioscience). The blots then 
were washed three times in TBST and incubated with the primary antibody directed against β-
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actin (1:10,000; Sigma-Aldrich). Images were captured with a Fuji LAS3000-mini imaging 
system (Fujifilm, Tokyo, Japan), and immunoreactive bands were quantified. 
Golgi Staining 
Golgi staining was performed using the FD Rapid GolgiStainTM Kit (FD Neuro Technologies, 
Inc., Columbia, MD), following the manufacturer's instructions (Zhang et al, 2015a; Ren et al, 
2015). Twenty-four hours after oral administration of vehicle (10 ml/kg), fluoxetine (10 mg/kg), 
brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg), animals 
were deeply anesthetized with sodium pentobarbital, and brains were removed from the skull 
and rinsed in double distilled water. Brains were immersed in the impregnation solution, made 
by mixing equal volumes of Solution A and B, overnight and then stored in fresh solution, for 
2 weeks in the dark. Brains were transferred into Solution C overnight and then stored in fresh 
solution at 4°C for 1 week, in the dark. Coronal brain sections (100 µm thickness) were cut on 
a cryostat (3050S, Leica Microsystems AG, Wetzlar, Germany), with the chamber temperature 
set at -20°C. Each section was mounted in Solution C, on saline-coated microscope slides. 
After absorption of excess solution, sections were dried naturally, at room temperature. Dried 
sections were processed following the manufacturer's instructions. Briefly, images of dendrites 
within CA1, CA3, and DG of the hippocampus, prelimbic (PrL) and inflalimbic (IL) areas of 
medial PFC (mPFC), and shell and core of NAc were captured using a 100× objective with a 
Keyence BZ-9000 GenerationⅡmicroscope (Osaka, Japan). Spines were counted along CA1, 
CA3, DG, PrL and IL of mPFC and NAc dendrites starting from their point of origin from the 
primary dendrite, as previously reported (Zhang et al, 2015a; Ren et al, 2015). For spine density 
measurements, all clearly evaluable areas containing 50-100 µm of secondary dendrites from 
each imaged neuron were used. To determine relative spine density, spines on multiple 
dendritic branches from a single neuron were counted to obtain an average spine number per 
10 µm. For spine number measurements, only spines that emerged perpendicular to the 
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dendritic shaft were counted. Three neurons per section, three sections per animal and six 
animals were analyzed. The average value for each region, in each individual was obtained. 
These individual averages were then combined to yield a grand average for each region. 
Statistical Analysis 
The data show as the mean ± standard error of the mean (S.E.M.). Analysis was performed 
using PASW Statistics 20 (formerly SPSS Statistics; SPSS). Comparisons between groups 
were performed using the one-way analysis of variance (ANOVA), followed by post hoc 
Fisher’s Least Significant Difference (LSD) tests. The P values of less than 0.05 were 
considered statistically significant. 
3. Results 
Effects of fluoxetine and brexpiprazole on depression-like behavior in susceptible mice 
after repeated social defeat stress 
We examined effects of fluoxetine and brexpiprazole on depression-like behavior after 
repeated social defeat stress. Vehicle, fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or 
fluoxetine plus brexpiprazole (0.1 mg/kg) was administered orally into susceptible mice 
(Figure 1a). In the locomotion test (LMT), there were no differences (F4,34 = 1.347, P = 0.276) 
among the five groups (Figure 1B). One-way ANOVA of TST and FST data revealed the 
statistical results (TST:  F4,33 = 6.139, P = 0.001, FST: F4,43 = 3.072, P = 0.027). In the TST and 
FST, combination of fluoxetine and brexpiprazole significantly reduced the increased 
immobility time in the susceptible mice after repeated social defeat stress (Figure 1c and 1d). 
One-way ANOVA of SPT data revealed the statistical result (F4,45 = 2.867, P =0.035). In the 
SPT, combination of fluoxetine and brexpiprazole significantly increased the decreased 
sucrose preference of susceptible mice whereas fluoxetine and brexpiprazole alone did not alter 
the sucrose preference (Figure 1e). In contrast, fluoxetine or brexpiprazole alone did not alter 
the immobility time for TST and FST, and decreased sucrose preference in the susceptible mice 
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(Figure 1c-1e).  These findings suggest that adjunctive treatment of brexpiprazole with 
fluoxetine showed a rapid antidepressant effect in the susceptible mice after repeated social 
defeat stress. 
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Figure 1. Antidepressant  effects of combination of brexpiprazole and fluoxetine in social 
defeat stress model. (a): Schedule of social defeat stress, treatment, and behavioral tests. 
Repeated social defeat stress was performed 10 days (day 1- day 10). Social interaction test 
was performed day 11, and susceptible mice were used subsequent experiments. Vehicle (10 
ml/kg), fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus 
brexpiprazole (0.1 mg/kg) were administered orally. Locomotion (LST), tail-suspension test 
(TST), and forced swimming test (FST) were performed 2, 4, and 6 hours after oral 
administration (day 12). One % sucrose preference test (SPT) was performed 24 hours after 
oral administration (day 13). (b): LMT, (c): TST, (d): FST, (e): SPT. Data are shown as mean 
± S.E.M. (n = 6–9). *P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle-treated stress 
group (one-way ANOVA, followed post hoc LSD test). N.S.: Not significant.  
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Effects of fluoxetine and brexpiprazole on BDNF-TrkB signaling in selected brain regions 
of mice with depression-like phenotype 
Since PFC, NAc, striatum, CA1, CA3 and dentate gyrus (DG) of the hippocampus play a role 
in the depression-like phenotype in rodents (Ren et al, 2015; Shirayama et al, 2015; Yang et 
al, 2015a; 2015b; Zhang et al, 2015a; 2015b), we performed Western blot analysis of BDNF 
(mature form), its precursor proBDNF, TrkB and phosphorylated TrkB (p-TrkB) in selected 
brain regions (PFC, NAc, striatum, DG, CA1 and CA3). One-way ANOVA of BDNF data 
revealed the statistical results (PFC: F4,28 = 3.871, P = 0.013, NAc: F4,27 = 18.79, P < 0.0001, 
striatum: F4,29 = 2.16, P = 0.099, CA1: F4,31 = 0.465, P = 0.761; CA3: F4,25 = 3.841, P = 0.014; 
DG: F4,27 = 5.53, P = 0.002) (Figure 2a-2f). Combination of brexpiprazole and fluoxetine 
significantly attenuated decreased BDNF levels in the PFC, CA3 and DG regions, but not CA1 
region, of susceptible mice (Figure 2a, 2d-2f). Interestingly, combination of brexpiprazole and 
fluoxetine significantly attenuated increased BDNF levels in the NAc of susceptible mice 
(Figure 2b). However, protein levels of proBDNF in the all regions were not different among 
the five groups (Figure 3a-3f). 
To clarify whether TrkB activation or inhibition underpins mechanistic action of 
brexpiprazole and fluoxetine combination, we performed Western blot analyses of TrkB and 
phosphorylated TrkB (p-TrkB), an activated form of TrkB, in samples from PFC, NAc, 
striatum, and CA1, CA3, DG of hippocampus. One-way ANOVA of p-TrkB/TrkB data 
revealed the statistical results (PFC: F4,26 = 10.55, P < 0.0001, NAc: F4,34 = 8.546, P < 0.0001, 
striatum: F4,28 = 0.775, P = 0.551, CA1: F4,29 = 0.879, P = 0.489; CA3: F4,26 = 5.794, P = 0.002; 
DG: F4,27 = 8.26, P = 0.0002) (Figure 2g-2l). Combination of brexpiprazole and fluoxetine 
significantly attenuated decreased p-TrkB/TrkB ratio in the PFC, CA3 and DG regions, but not 
CA1 region, of susceptible mice (Figure 2g, 2k, 2l). Interestingly, combination of 
brexpiprazole and fluoxetine significantly attenuated increased p-TrkB/TrkB ratio in the NAc 
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of susceptible mice (Figure 2h). However, protein levels of TrkB in the all regions were not 
different among the five groups (PFC: F4,30 = 2.327, P = 0.079, NAc: F4,25 = 2.289, P = 0.088, 
striatum: F4,27 = 0.369, P = 0.829, CA1: F4,30 = 0.309, P = 0.87, CA3: F4,33 = 0.504, P = 0.733, 
DG: F4,28 = 0.214, P = 0.928) (Figure 3g-3l). 
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Figure 2. Effects of brexpiprazole and fluoxetine combination on the alterations in the 
BDNF-TrkB signaling in the brain regions from susceptible mice after social defeat stress. 
(a–f): Forty eight hours after administration of drugs, brain regions from mice were collected. 
Western blot analysis of BDNF (mature form) and β-actin in the brain regions (PFC, NAc, 
striatum, CA1, CA3, DG) was performed. e values are expressed as a percentage of that of 
control mice. Representative data of Western blot analyses of BDNF and β-actin in the mouse 
brain regions. Data are shown as mean ± S.E.M. (n = 5–8). *P < 0.05, **P < 0.01, ***P < 0.001 
compared to vehicle-treated stress group (one-way ANOVA, followed post hoc LSD test). N.S.: 
Not significant. (g–l): e ratio of p-TrkB to total TrkB in the brain regions is shown. e values 
are expressed as a percentage of that of control mice. Representative data of Western blot 
analyses of p-TrkB, and TrkB in the mouse brain regions. Data are shown as mean ± S.E.M. 
(n = 5–8). *P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle-treated stress group (one-
way ANOVA, followed post hoc LSD test). N.S.: Not significant.  
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Figure 3. Effects of brexpiprazole and fluoxetine on the levels of proBDNF and TrkB in 
the brain regions (a-f): Forty eight hours after administration of drugs, brain regions from 
mice were collected. Western blot analysis of proBDNF and β-actin in the brain regions (PFC, 
NAc, striatum, CA1, CA3, DG) was performed. The values are expressed as a percentage of 
that of control mice. Representative data of Western blot analyses of proBDNF and β-actin in 
the mouse brain regions. Data are shown as mean ± S.E.M. (n = 5 - 8). N.S.: Not significant. 
(g-l): Western blot analysis of TrkB and β-actin in the brain regions (PFC, NAc, striatum, CA1, 
CA3, DG) was performed. Representative data of Western blot analyses of TrkB, and β-actin 
in the mouse brain regions. The values are expressed as a percentage of that of control mice. 
Data are shown as mean ± S.E.M. (n = 5 - 8). N.S.: Not significant. 
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Effects of fluoxetine and brexpiprazole on alterations in the dendritic spine density in 
selected brain regions of mice with depression-like phenotype 
Repeated social defeat stress causes alterations in the dendritic spine density in the PFC, CA3 
and DG of hippocampus, and NAc (Zhang et al, 2015b; Yang et al, 2015b). In this study, we 
examined whether combination of brexpiprazole and fluoxetine could affect alterations in the 
dendritic spine density in the prelimbic (PrL) and infralimbic (IL) regions of mPFC, shell and 
core of NAc, CA1, CA3 and DG of the hippocampus (Figure 4a). One-way ANOVA of Golgi 
staining data revealed the statistical results (PrL of mPFC: F4,21 = 158.0, P < 0.0001, IL of 
mPFC: F4,20 = 2.44, P = 0.08, NAc core: F4,20 = 3.305, P = 0.042, NAc shell: F4,20 = 2.96, P = 
0.045, CA1: F4,21 = 2.294, P = 0.093; CA3: F4,21 = 28.79, P < 0.0001; DG: F4,21 = 20.51, P < 
0.0001) (Figure 4b-4i). Combination of brexpiprazole and fluoxetine significantly attenuated 
decreased spine density in the PrL of mPFC, CA3 and DG regions of susceptible mice (Figure 
4b, 4g, 4h). Interestingly, combination of brexpiprazole and fluoxetine significantly attenuated 
increased spine density in the core and shell of NAc of susceptible mice (Figure 4d, 4e).  In 
contrast, administration of brexpiprazole or fluoxetine alone did not alter alterations in the 
dendritic spine density in these regions (Figure 4b-4h). 
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Figure 4. Effects of brexpiprazole and fluoxetine combination on the alterations in the 
dendritic spine density in the brain regions from susceptible mice after social defeat stress. 
(a): Schedule of social defeat stress, treatment, and behavioral tests. Repeated social defeat 
stress was performed 10 days (day 1- day 10). Social interaction test was performed day 11, 
and susceptible mice were used subsequent experiments. Two hours after oral administration 
of vehicle (10 ml/kg), fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 
mg/kg) plus brexpiprazole (0.1 mg/kg), brains from mice were collected for Golgi 
staining. (b–h): Golgi staining in the brain regions (PrL and IL regions of mPFC, core and 
shell of NAc, CA1, CA3, DG of hippocampus) was performed. Representative data of Golgi 
staining in the mouse brain regions. Data are shown as mean ± S.E.M. (n = 5 or 6). *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to vehicle-treated stress group (one- way ANOVA, 
followed post hoc LSD test). N.S.: Not significant.  
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Role of TrkB in the mechanistic action of brexpiprazole and fluoxetine combination in 
social defeat stress model 
To assess the role of TrkB on the mechanistic action of combination of brexpiprazole and 
fluoxetine, we examined the effects of ANA-12, a novel TrkB antagonist (Cazorla et al, 2011), 
on depression-like behavior after social defeat stress (Figure 5a). One-way ANOVA of the 
behavioral data showed statistical results (LMT: F4,35 = 0.287, P = 0.884, TST: F4,34 = 6.163, P 
= 0.0008, FST: F4,33 = 12.73, P < 0.0001, SPT: F4,33 = 9.022, P < 0.0001) (Figure 5b-5e). In the 
TST and FST, treatment with ANA-12 significantly blocked the effects of brexpiprazole plus 
fluoxetine on the increased immobility time of susceptible mice (Figure 5c and 5d). 
Furthermore, treatment with ANA-12 significantly blocked the effects of brexpiprazole plus 
fluoxetine on the decreased sucrose preference of susceptible mice (Figure 5e). In addition, 
ANA-12 alone showed antidepressant effects in these tests, consistent with previous reports 
(Zhang et al, 2015a; 2015b; Yang et al, 2015b). 
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Figure 5. Effects of TrkB antagonist ANA-12 on antidepressant effect of combination of 
brexpiprazole and fluoxetine. (a): Schedule of social defeat stress, treatment, and behavioral 
tests. Repeated social defeat stress was performed 10 days (day 1- day 10). Social interaction 
test was performed day 11, and susceptible mice were used subsequent experiments. Vehicle 
(10 ml/kg), fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus 
brexpiprazole (0.1 mg/kg) were administered orally 30 min after administration of vehicle or 
ANA-12 (0.5 mg/kg). Locomotion (LST), tail-suspension test (TST), and forced swimming 
test (FST) were performed 2, 4, and 6 hours after oral administration (day 12). One % sucrose 
preference test (SPT) was performed 24 hours after oral administration (day 13). (b): LMT, (c): 
TST, (d): FST, (e): SPT. Data are shown as mean ± S.E.M. (n = 6–9). *P < 0.05, **P < 0.01, 
***P < 0.001 compared to vehicle-treated stress group (one-way ANOVA, followed post hoc 
LSD test). N.S.: Not significant.  
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Role of BDNF-TrkB signaling in the mechanistic action of brexpiprazole and fluoxetine 
combination 
Since TrkB antagonist ANA-12 blocked antidepressant effect of brexpiprazole and fluoxetine 
combination in the social defeat stress model, we performed Western blot analysis of BDNF-
TrkB signaling in the brain regions. One-way ANOVA of BDNF data showed statistical results 
(PFC: F4,28 = 25.33, P < 0.0001, NAc: F4,25 = 5.887, P = 0.002, striatum: F4,27 = 1.153, P = 0.353, 
CA1: F4,26 = 0.311, P = 0.868, CA3: F4,26 = 4.923, P = 0.004, DG: F4,31 =4.629, P = 
0.005)(Figure 6a-6f). Combination of brexpiprazole and fluoxetine significantly attenuated 
decreased levels of BDNF in the PFC, CA3, and DG from susceptible mice after social defeat 
stress (Figure 6a, 6e, 6f). However, treatment with ANA-12 did not alter levels of BDNF in 
these brain regions. 
One-way ANOVA of p-TrkB/TrkB ratio data showed statistical results (PFC: F4,33 = 
3.728, P = 0.016, NAc: F4,33 = 9.342, P < 0.0001, striatum: F4,33 = 1.153, P = 0.353, CA1: F4,27 
= 0.971, P = 0.440, CA3: F4,31 =7.889, P = 0.0002, DG: F4,33 = 12.92, P < 0.0001) (Figure 6g-
6l). Combination of brexpiprazole and fluoxetine significantly attenuated decreased p-
TrkB/TrkB ratio in the PFC, CA3, and DG from susceptible mice after social defeat stress 
(Figure 6g, 6k, 6l). Furthermore, treatment with ANA-12 significantly blocked the effect of 
brexpiprazole plus fluoxetine combination in these regions (PFC, CA3, DG), suggesting a role 
of TrkB in the mechanistic action of the combination therapy. Although combination of 
brexpiprazole and fluoxetine significantly attenuated increased p-TrkB/TrkB ratio in the NAc 
from susceptible mice, ANA-12 did not block the effect of the combination (Figure 6h). 
However, treatment with ANA-12 alone significantly attenuate increase p-TrkB/TrkB ratio in 
the NAc of susceptible mice, consistent with previous reports (Zhang et al, 2015a; 2015b; Yang 
et al, 2015b). Protein levels of proBDNF and TrkB in the all brain regions were not different 
among the five groups (proBDNF, PFC: F4,35 = 0.505, P = 0.732, NAc: F4,29 = 1.147, P = 0.354, 
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striatum: F4,27 = 0.108, P = 0.979, CA1: F4,25 0.936, P = 0.46, CA3: F4,32 = 0.63, P = 0.645, DG: 
F4,33 = 0.531, P = 0.714)(TrkB, PFC: F4,33 =0.646, P = 0.634, NAc: F4,29 = 0.114, P = 0.977, 
striatum: F4,31 = 0.821, P = 0.522, CA1: F4,25 = 0.522, P = 0.721, CA3: F4,26 = 0.341, P = 0.848, 
DG: F4,32 = 1.106, P = 0.371)( Figure 7). 
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Figure 6. Effect of TrkB antagonist ANA-12 on the alterations in the BDNF-TrkB 
signaling in the brain regions from susceptible mice after social defeat stress. (a–f): Forty 
eight hours after administration of drugs, brain regions from mice were collected. Western blot 
analysis of BDNF (mature form) and β-actin in the brain regions (PFC, NAc, striatum, CA1, 
CA3, DG) was performed. e values are expressed as a percentage of that of control mice. Data 
are shown as mean ± S.E.M. (n = 6–8). *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
vehicle-treated stress group (one-way ANOVA, followed post hoc LSD test). N.S.: Not 
significant. (g–l): e ratio of p-TrkB to total TrkB in the brain regions is shown. Representative 
data of Western blot analyses of p-TrkB, and TrkB in the mouse brain regions. e values are 
expressed as a percentage of that of control mice. Data are shown as mean ± S.E.M. (n = 6–8). 
*P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle-treated stress group (one-way 
ANOVA, followed post hoc LSD test). N.S.: Not significant.  
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Figure 7. Effects of ANA-12 on the levels of proBDNF and TrkB in the brain regions (a-
f): Forty eight hours after administration of drugs, brain regions from mice were collected. 
Western blot analysis of proBDNF and β-actin in the brain regions (PFC, NAc, striatum, CA1, 
CA3, DG) was performed. The values are expressed as a percentage of that of control mice. 
Representative data of Western blot analyses of proBDNF and β-actin in the mouse brain 
regions. Data are shown as mean ± S.E.M. (n = 6 - 8). N.S.: Not significant. (g-l): Western blot 
analysis of TrkB and β-actin in the brain regions (PFC, NAc, striatum, CA1, CA3, DG) was 
performed. Representative data of Western blot analyses of TrkB, and β-actin in the mouse 
brain regions. The values are expressed as a percentage of that of control mice. Data are shown 
as mean ± S.E.M. (n = 6 - 8). N.S.: Not significant. 
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4. Discussion 
The major findings of this study are that combination of brexpiprazole and fluoxetine could 
promote a rapid antidepressant effect in the social defeat stress model of depression, although 
brexpipazole or fluoxetine alone did not show antidepressant effect. Recently, we reported a 
rapid antidepressant effect of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine 
(or R-ketamine) in the same model (Yang et al, 2015b; Zhang et al, 2015b), indicating that a 
rapid antidepressant effect of combination of brexpiprazole and fluoxetine is similar to 
ketamine’s rapid antidepressant action. A recent study demonstrated that, similar to ketamine, 
a combination of olanzapine and fluoxetine facilitated NMDA- and AMPA-induced currents 
in pyramidal cells via activation of dopamine D1 receptors (Björkholm et al, 2015), suggesting 
that rapid antidepressant effect of both antipsychotic drug and SSRI may be related to a 
common mechanism of action. To the best of our knowledge, this is the first report showing a 
rapid antidepressant effect for brexpiprazole plus fluoxetine in the social defeat stress model. 
Therefore, adjunction therapy of brexpiprazole to SSRI could promote a rapid antidepressant 
effect in MDD patients. Interestingly, TrkB antagonist ANA-12 significantly blocked a rapid 
antidepressant effect of combination of brexpiprazole and fluoxetine in this model. Given the 
role of BDNF-TrkB signaling in the antidepressant effects of ketamine (Autry et al, 2011; 
Lepack et al, 2014; Liu et al, 2016; Sun et al, 2016; Yang et al, 2015b), it is likely that BDNF-
TrkB signaling plays a key role in the rapid antidepressant effect of combination of 
brexpiprazole and fluoxetine in the social defeat stress model. 
We previously reported a marked reduction of BDNF-TrkB signaling in the PFC, DG 
and CA3, but not CA1, of inflammation model (Zhang et al, 2015a), repeated social defeat 
stress model (Zhang et al, 2015b; Yang et al, 2015b) and learned helplessness model 
(Shirayama et al, 2015; Yang et al, 2015a). Direct infusion of BDNF (or TrkB agonist 7,8-
dihydroxyflavone (7,8-DHF) (Jang et al, 2010)) into the DG and CA3, but not CA1, promoted 
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rapid and sustained antidepressant effects in the rat learned helplessness model of depression 
(Shirayama et al, 2002; 2015), implicating BDNF-TrkB signal pathway in the DG, and CA3, 
but not CA1, in the antidepressant action of BDNF or TrkB agonist. This is consistent with 
decreased BDNF protein levels in the PFC, DG, CA3, but not CA1, in rat learned helplessness 
model (Shirayama et al, 2015; Yang et al, 2015a). In this study, we found that combination of 
brexpiprazole and fluoxetine could attenuate decreased BDNF-TrkB signaling in the PFC, CA3, 
and DG from susceptible mice after social defeat stress. We also reported that 7,8-DHF 
promoted a rapid antidepressant effect in social defeat stress model (Zhang et al, 2015b). 
Therefore, it is likely that combination of brexpiprazole and fluoxetine might promote a rapid 
antidepressant effect by stimulating BDNF-TrkB pathway in these regions. 
In contrast, the ventral tegmental area (VTA)-NAc pathway plays a critical role in the 
depression-phenotype (Nestler and Carlezon 2006; Shirayama et al, 2015; Zhang et al, 2015a; 
2015b; Yang et al, 2015a). We reported that inflammation, social defeat stress and learned 
helplessness caused an increased BDNF-TrkB signaling within the NAc (Zhang et al, 2015a; 
2015b; Shirayama et al, 2015; Yang et al, 2015a; 2015b). Thus, social defeat stress causes 
decreased BDNF-TrkB signaling in the hippocampus and PFC, but increased BDNF-TrkB 
signaling in the NAc, resulting in depression-like behavior in mice. Interestingly, we found 
that combination of brexpiprazole and fluoxetine could attenuate alterations in the BDNF-TrkB 
signaling in the PFC, hippocampus as well as NAc. In contrast, we found that ketamine did not 
alter the increased levels of BDNF in the NAc from susceptible mice after social defeat stress 
(Zhang et al, 2015b; Yang et al, 2015b), suggesting that ketamine can induce the rapid and 
log-lasting antidepressant effects by increasing BDNF in the PFC and hippocampus, but not in 
NAc. It is noteworthy that combination of brexpiprazole and fluoxetine could improve 
alterations in the BDNF-TrkB signaling in the NAc from susceptible mice after social defeat 
stress. 
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Changes in dendritic length and spine density in the PFC and hippocampus are thought 
to contribute to the neurobiology of depression, and antidepressant treatment is mediated, in 
part, by blocking or reversing these changes (Duman and Aghajanian, 2012; Ohgi et al, 2015; 
McEwen, 2007). Recently, we reported that ketamine or R-ketamine showed a rapid 
antidepressant activity by normalizing altered dendritic spines in the PFC and hippocampus, 
but not NAc (Zhang et al, 2015b; Yang et al, 2015b). In addition, we also reported that 
ketamine did not show antidepressant effect in depression-like behavior induced by increased 
BDNF-TrkB signaling in the NAc after methamphetamine withdrawal (Ren et al, 2015). 
Together, it is likely that NAc may not be involved in the antidepressant effect of ketamine. A 
single administration of 7,8-DHF or  ANA-12 could normalize alterations in spine density in 
the social defeat stress model by stimulation at TrkB in the PFC, CA3, and DG, as well as 
blockade of TrkB in the NAc (Zhang et al, 2015b). Therefore, it is likely that combination of 
brexpiprazole and fluoxetine could act by normalizing altered dendritic spine density in the all 
regions such as PFC, hippocampus, and NAc. Therefore, it is likely that, unlike to ketamine, 
BDNF-TrkB signaling in NAc might be necessary to mediate the antidepressant effect of 
brexpiprazole plus fluoxetine, although further studies are needed. 
In conclusion, this study shows that adjunction of brexpiprazole to fluoxetine can 
produce a rapid antidepressant effect in the social defeat stress model of depression and that 
BDNF-TrkB signaling plays a role in the rapid antidepressant action of the combination 
therapy. Therefore, it is likely that adjunction of brexpiprazole to SSRI could produce a rapid 
antidepressant effect in treatment-resistant patients with MDD, without ketamine-induced 
psychotomimetic effects and abuse potential. 
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 III. CHAPTER II 
 
Antidepressant effects of combination of brexpiprazole and fluoxetine on 
depression-like behavior and dendritic changes in mice after inflammation  
1. Background  
Accumulating evidence suggests that inflammation plays a role in the pathophysiology of 
major depressive disorder (MDD) (Dantzer et al. 2008; Hashimoto 2015; Miller and Raison 
2015; Strawbridge et al. 2015). A meta-analysis shows higher blood levels of pro-inflammatory 
cytokines in drug-free depressed patients, compared with healthy controls (Dowlati et al. 2010). 
Peripheral administration of the bacterial endotoxin lipopolysaccharide (LPS) induces 
depression-like behavior in rodents after the induction of inflammation (Dantzer et al. 2008; 
O’Connor et al. 2009; Remus and Dantzer 2016; Zhang et al. 2016). LPS-induced depression-
like behavior can be blocked by pretreatment with antidepressants, including selective 
serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) 
(Dong et al. 2016; Ma et al. 2014; Ohgi et al. 2013; Yao et al. 2014). These findings suggest 
that inflammation might be associated with depressive symptoms.  
Several clinical studies demonstrate that addition of low doses of atypical antipsychotic 
drugs (e.g., aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) to SSRIs to rapidly 
enhance the antidepressant effects in depressed patients, including treatment-resistant patients 
(Barbee et al. 2004; Brunner et al. 2014; Nelson and Papakostas 2009; Ozaki et al. 2015; 
Papakostas et al. 2005; 2007; 2015; Rogóz 2013; Shelton and Papakostas 2008). Brexpiprazole 
(7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one), a serotonin-
dopamine activity modulator, binds with high affinity (Ki < 1 nM) to human serotonin (5-HT) 
5-HT1A, 5-HT2A-, dopamine D2 (D2L)- and adrenergic α1B-, α2C-receptors. It displays partial 
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agonism at 5-HT1A and D2 receptors, and potent antagonism of 5-HT2A receptors and α1B/2C-
adrenoceptors (Maeda et al. 2014a). Furthermore, brexpiprazole could potentiate nerve growth 
factor (NGF)-induced neurite outgrowth in PC12 cells via 5-HT1A and 5-HT2A receptors 
(Ishima et al. 2015). Moreover, brexpiprazole showed antipsychotic-like and procognitive 
effects in rodents (Maeda et al. 2014b; Yoshimi et al. 2014; 2015). Brexpiprazole has shown 
efficacy as adjunctive treatment of MDD (Citrome 2015; McKeage 2016; Stahl 2016; Thase et 
al. 2015a; 2015b).  
The purpose of this study is to examine whether combination of brexpiprazole and SSRI 
fluoxetine could improve depression-like behaviors and alterations in the brain-derived 
neurotrophic factor (BDNF) - TrkB signaling, and dendritic spine density in the selected brain 
regions after a single LPS administration.  
2. Material and methods 
Animals 
Male adult C57BL/6 mice (8 weeks old) weighing 20–25 g were purchased from SLC Japan 
(Hamamatsu, Shizuoka, Japan). The mice were housed in clear polycarbonate cages 
(22.5 × 33.8 × 14.0 cm) in groups of 4 or 5 individuals under a controlled 12/12-h light–dark 
cycle (light from 7:00 AM to 7:00 PM), with the room temperature kept at 23 °C ± 1 °C and 
humidity at 55% ± 5%. The mice were given free access to water and food pellets specifically 
designed for mice. The experimental procedure was approved by the Animal Care and Use 
Committee of Chiba University Graduate School of Medicine. 
Drugs and drug administration 
LPS (0.5 mg/kg; L-4130, serotype 0111:B4, Sigma-Aldrich, St Louis, MO, USA) was 
dissolved in distilled water. Saline (10 ml/kg) or LPS (0.5 mg/kg) was administered 
intraperitoneally (i.p.). Brexpiprazole was synthesized at Otsuka Pharmaceutical Co., Ltd. 
(Tokyo, Japan). Vehicle (0.5% CMC; 10 ml/kg), fluoxetine (10 mg/kg, Wako Chemical Co., 
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Ltd., Tokyo, Japan), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole 
(0.1 mg/kg) were administered orally. The doses of brexpiprazole (0.1 mg/kg) and fluoxetine 
(10 mg/kg) were selected as reported previously (Maeda et al. 2014a; 2014b; Rogóz 2013; 
Yoshimi et al. 2015). Other chemicals were purchased from commercial sources. 
Behavioral tests 
Behavioral tests were performed as previously reported (Ren et al. 2015; 2016; Yang et al. 
2015b; Zhang et al. 2015a; 2015b). 
Locomotion: Mice were placed in experimental cages (L560×W560×H330 mm), and 
locomotor activity was counted by the SCANET MV-40 (MELQUEST, Toyama, Japan). The 
cumulative exercise was recorded for 60 min. All cages were cleaned between testing session. 
Tail suspension test: A small piece of adhesive tape was placed at 2 cm from the tip of the tail 
and punched with a single hole that serves to hang the mice on a hook. The immobility time of 
each mouse was recorded for 10min. Mice were considered immobile only when they hung 
passively and completely motionless. 
Forced swim test: Animals were tested in an automated forced-swim apparatus using 
SCANET MV-40 (MELQUEST Co., Ltd., Toyama, Japan). The mice were placed individually 
in a cylinder (Diameter 23cm; Height 21cm), containing 15 cm of 23 ± 1°C warm water. 
Immobility time was calculated by subtracting active time from total time, using the apparatus 
analysis software. Cumulative immobility time was scored for 6 min during the test. The TST 
and FST were performed 2 and 4 h after the LMT, respectively 
Western blot analysis of BDNF, and its precursor proBDNF, TrkB, and phosphorylated-
TrkB  
Western blot analysis was performed as reported previously (Ren et al. 2015; 2016; Yang et 
al. 2015b; Zhang et al. 2015a; 2015b). Mice were killed by cervical dislocation and brains were 
rapidly removed from the skull. Approximately 1 mm thick coronal sections were cut and 
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bilateral tissue punches of prefrontal cortex (PFC), nucleus accumbens (NAc), striatum, CA1, 
CA3, and dentate gyrus (DG) of the hippocampus were dissected on ice using a SZ-LED Kenis 
light microscope (Osaka, Japan), and stored at −80°C. Tissue samples were homogenized in 
Laemmli lysis buffer. Aliquots (20 µg) of protein were measured using the DC protein assay 
kit (Bio-Rad), and incubated for 5 min at 95°C,with an equal volume of 125mM Tris-HCl, pH 
6.8, 20% glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol, 4% SDS, and subjected 
to SDS polyacrylamide gel electrophoresis using AnyKD minigels (Mini-PROTEAN TGX 
Precast Gel; BioRad). Proteins were transferred onto PVDF membranes using a Trans Blot 
Mini Cell (Bio-Rad). For immunodetection, the blots were blocked with 2% BSA in TBST 
(TBS + 0.1% Tween-20) for 1 h at room temperature, and kept with primary antibodies 
overnight at 4 °C. The following primary antibodies were used: BDNF (1:200; H-117, Cat#: 
sc-20981, Santa Cruz Biotechnology), phosphor-TrkB (Tyr-706) (1:200; Cat#: sc135645, 
Santa Cruz Biotechnology), TrkB (80E3) (1:1,000; Cat#: 4603, Cell Signaling Technology). 
The next day, blots were washed three times in TBST, and incubated with horseradish 
peroxidase-conjugated anti-rabbit antibody (1:10,000) 1 h, at room temperature. After a final 
three washes with TBST, bands were detected using enhanced chemiluminescence (ECL) plus 
the Western Blotting Detection system (GE Healthcare Bioscience). The blots were then 
washed three times in TBST and incubated with the primary antibody directed against β-actin 
(1:10,000; Sigma-Aldrich). Images were captured with a Fuji LAS3000-mini imaging system 
(Fujifilm, Tokyo, Japan), and immunoreactive bands were quantified. 
Golgi Staining 
Golgi staining was performed using the FD Rapid GolgiStainTM Kit (FD Neuro Technologies, 
Inc., Columbia, MD), following the manufacturer's instructions (Zhang et al. 2015a; Ren et al. 
2015). Two hours after oral administration of vehicle (10 ml/kg), fluoxetine (10 mg/kg), 
brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg), animals 
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were deeply anesthetized with sodium pentobarbital, and brains were removed from the skull 
and rinsed in double distilled water. Brains were immersed in the impregnation solution, made 
by mixing equal volumes of Solution A and B, overnight and then stored in fresh solution, for 
2 weeks in the dark. Brains were transferred into Solution C overnight and then stored in fresh 
solution at 4°C for 1 week, in the dark. Coronal brain sections (100 µm thickness) were cut on 
a cryostat (3050S, Leica Microsystems AG, Wetzlar, Germany), with the chamber temperature 
set at -20°C. Each section was mounted in Solution C, on saline-coated microscope slides. 
After absorption of excess solution, sections were dried naturally, at room temperature. Dried 
sections were processed following the manufacturer's instructions. Briefly, images of dendrites 
within CA1, CA3, and DG of the hippocampus, prelimbic (PrL) and inflalimbic (IL) areas of 
medial PFC (mPFC), and shell and core of NAc were captured using a 100× objective with a 
Keyence BZ-9000 GenerationⅡmicroscope (Osaka, Japan). Spines were counted along CA1, 
CA3, DG, PrL and IL of mPFC, and shell and core of NAc dendrites starting from their point 
of origin from the primary dendrite, as previously reported (Zhang et al. 2015a; Ren et al. 
2015). For spine density measurements, all clearly evaluable areas containing 50-100 µm of 
secondary dendrites from each imaged neuron were used. To determine relative spine density, 
spines on multiple dendritic branches from a single neuron were counted to obtain an average 
spine number per 10 µm. For spine number measurements, only spines that emerged 
perpendicular to the dendritic shaft were counted. Three neurons per section, three sections per 
animal and six animals were analyzed. The average value for each region, in each individual 
was obtained. These individual averages were then combined to yield a grand average for each 
region. 
Statistical Analysis 
The data show as the mean ± standard error of the mean (S.E.M.). Analysis was performed 
using PASW Statistics 20 (formerly SPSS Statistics; Tokyo, Japan). Comparisons between 
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groups were performed using the one-way analysis of variance (ANOVA), followed by post 
hoc Fisher’s Least Significant Difference (LSD) tests. The P values of less than 0.05 were 
considered statistically significant. 
3. Result 
Effects of fluoxetine and brexpiprazole on depression-like behavior in mice after LPS 
administration 
Vehicle, fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus 
brexpiprazole (0.1 mg/kg) was administered orally into mice 22 hours after LPS (0.5 mg/kg) 
administration (Figure 1A). In the locomotion test (LMT), there were no differences (F4,38 = 
0.819, P = 0.522) among the five groups (Figure 1B). One-way ANOVA of TST and FST data 
revealed the statistical results (TST (Figure 1C)):  F4,38 = 4.922, P = 0.003, FST ((Figure 1D): 
F4,38 = 7.346, P < 0.0001). In the TST and FST, combination of fluoxetine and brexpiprazole 
significantly attenuated the increased immobility time in mice after LPS administration (Figure 
1C and 1D). In contrast, fluoxetine or brexpiprazole alone did not alter the increased 
immobility time for TST and FST after LPS administration (Figure 1C and 1D).  These findings 
suggest that adjunctive treatment of brexpiprazole with fluoxetine showed a rapid 
antidepressant effect on LPS-induced depression model. 
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Figure 1. Antidepressant effects of combination of brexpiprazole and fluoxetine in 
inflammation model  
(A): Schedule of treatment, and behavioral tests. Saline (10 ml/kg) or LPS (0.5 mg/kg) was 
administered i.p. into mice. Vehicle (10 ml/kg), fluoxetine (10 mg/kg), brexpiprazole (0.1 
mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) were administered orally 22 
hours after LPS administration. Locomotion (LST), tail-suspension test (TST), and forced 
swimming test (FST) were performed 2, 4, and 6 hours after oral administration. (B): LMT, 
(C): TST, (D): FST. Data are shown as mean ± S.E.M. (n = 6-9). *P < 0.05, **P < 0.01, ***P 
< 0.001 compared to vehicle-treated LPS group (one-way ANOVA, followed post hoc LSD 
test). N.S.: Not significant. Veh: Vehicle, Flu: Fluoxetine, Brex: Brexpiprazole. 
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Effects of fluoxetine and brexpiprazole on BDNF-TrkB signaling in selected brain regions 
of mice after LPS administration 
Since PFC, NAc, striatum, CA1, CA3 and dentate gyrus (DG) of the hippocampus play a role 
in the depression-like phenotype in rodents (Ren et al. 2015; Shirayama et al. 2015; Yang et 
al. 2015a; 2015b; Zhang et al. 2015a; 2015b), we performed Western blot analysis of BDNF 
(mature form), its precursor proBDNF, TrkB and phosphorylated TrkB (p-TrkB) in selected 
brain regions (PFC, NAc, striatum, DG, CA1 and CA3). Vehicle, fluoxetine (10 mg/kg), 
brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) was 
administered orally into mice 22 hours after LPS administration (Figure 2A). Brain regions 
were collected 2 hours after oral administration (Figure 2A). One-way ANOVA of BDNF data 
revealed the statistical results (PFC: F4,31 = 5.785, P = 0.0013, NAc: F4,33 = 5.896, P = 0.0011, 
striatum: F4,25 = 1.165, P = 0.35, CA1: F4,27 = 0.501, P = 0.736; CA3: F4,30 = 7.265, P = 0.0003; 
DG: F4,32 = 17.24, P < 0.0001)(Figure 2B-2G). Combination of brexpiprazole and fluoxetine 
significantly attenuated decreased BDNF levels in the PFC, CA3 and DG regions after LPS 
administration (Figure 2B, 2F, 2G). Furthermore, combination of brexpiprazole and fluoxetine 
significantly attenuated increased BDNF levels in the NAc after LPS administration (Figure 
2C). However, no regional differences of proBDNF protein levels were observed among the 
five groups (Figure 2H-2M). 
	 43	
 
 
Figure 2. Effects of brexpiprazole and fluoxetine combination on the alterations in the 
BDNF and proBDNF in the brain regions after LPS administration  
(A): Schedule of treatment, and collection of brain samples. Vehicle (10 ml/kg), fluoxetine (10 
mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) 
were administered orally 22 hours after saline or LPS (0.5 mg/kg) administration. Brain regions 
were collected 2 hours after administration of drugs. Western blot analysis of proBDNF (B-G), 
BDNF (mature form)(H-M) and β-actin in the brain regions (PFC, NAc, striatum, CA1, CA3, 
DG) was performed. (B, H): PFC, (C, I): NAc, (D, J): striatum, (E, K): CA1, (F, I): CA3, (G, 
M): DG. The values are expressed as a percentage of that of control mice. Representative data 
of Western blot analyses of proBDNF, BDNF and β-actin in the mouse brain regions. Data are 
shown as mean ± S.E.M. (n = 6-8). *P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle-
treated LPS group (one-way ANOVA, followed post hoc LSD test). N.S.: Not significant, Veh: 
Vehicle, Flu: Fluoxetine, Brex: Brexpiprazole. 
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To clarify whether TrkB activation or inhibition underpins mechanistic action of 
brexpiprazole and fluoxetine combination, we performed Western blot analyses of TrkB and 
phosphorylated TrkB (p-TrkB), an activated form of TrkB, in samples from PFC, NAc, 
striatum, and CA1, CA3, DG of hippocampus. One-way ANOVA of p-TrkB/TrkB data 
revealed the statistical results (PFC: F4,27 = 3.179, P = 0.029, NAc: F4,27 = 17.67, P < 0.0001, 
striatum: F4,30 = 0.35, P = 0.842, CA1: F4,30 = 0.256, P = 0.904; CA3: F4,26 = 8.607, P = 0.0001; 
DG: F4,25 = 8.62, P = 0.0002) (Figure 3A-3F). Combination of brexpiprazole and fluoxetine 
significantly attenuated LPS-induced decrease of p-TrkB/TrkB ratio in the PFC, CA3 and DG 
regions (Figure 3A, 3E, 3F). Furthermore, combination of brexpiprazole and fluoxetine 
significantly attenuated increased p-TrkB/TrkB ratio in the NAc after LPS administration 
(Figure 3B). However, no regional differences of TrkB protein levels were observed among 
the five groups (data not shown). 
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Figure 3. Effects of brexpiprazole and fluoxetine combination on the alterations in the 
phosphorylation of TrkB in the brain regions after LPS administration  
(A-F): The ratio of p-TrkB to total TrkB in the brain regions is shown. Representative data of 
Western blot analyses of p-TrkB, and TRkB in the mouse brain regions. The values are 
expressed as a percentage of that of control mice. Representative data of Western blot analyses 
of BDNF and β-actin in the mouse brain regions. Data are shown as mean ± S.E.M. (n = 5-8). 
*P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle-treated LPS group (one-way ANOVA, 
followed post hoc LSD test). N.S.: Not significant, Veh: Vehicle, Flu: Fluoxetine, Brex: 
Brexpiprazole. 
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Effects of fluoxetine and brexpiprazole on alterations in the dendritic spine density in 
selected brain regions of mice after LPS administration 
A single administration of LPS (0.5 mg/kg) causes alterations in the dendritic spine density in 
the PFC, CA3 and DG of hippocampus, and NAc (Zhang et al. 2015a). In this study, we 
examined whether combination of brexpiprazole and fluoxetine could affect alterations in the 
dendritic spine density in the prelimbic (PrL) and infralimbic (IL) regions of mPFC, shell and 
core of NAc, CA1, CA3 and DG of the hippocampus. Vehicle, fluoxetine (10 mg/kg), 
brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) was 
administered orally into mice 22 hours after LPS administration (Figure 4A). Brain regions 
were collected 2 hours after oral administration (Figure 4A). One-way ANOVA of Golgi 
staining data revealed the statistical results (PrL of mPFC: F4,24 = 16.042, P < 0.0001, IL of 
mPFC: F4,24 = 1.236, P = 0.327, NAc core: F4,24 = 18.003, P < 0.0001, NAc shell: F4,24 = 12.501, 
P < 0.0001, CA1: F4,26 = 1.949, P = 0.138; CA3: F4,26 = 79.66, P < 0.0001; DG: F4,26 = 229.97, 
P < 0.0001) (Figure 4B-4H). Combination of brexpiprazole and fluoxetine significantly 
attenuated the LPS-induced decrease of spine density in the PrL of mPFC, CA3 and DG regions 
(Figure 4B, 4F, 4G). Furthermore, combination of brexpiprazole and fluoxetine significantly 
attenuated LPS-induced increase of spine density in the core and shell of NAc (Figure 4D, 4E).  
In contrast, administration of brexpiprazole or fluoxetine alone did not alter alterations in the 
dendritic spine density in these regions after LPS administration (Figure 4B-4H). 
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Figure 4. Effects of brexpiprazole and fluoxetine combination on the alterations in the 
dendritic spine density in the brain regions after LPS administration 
(A): Schedule of treatment, and collection of brain samples. Vehicle (10 ml/kg), fluoxetine (10 
mg/kg), brexpiprazole (0.1 mg/kg), or fluoxetine (10 mg/kg) plus brexpiprazole (0.1 mg/kg) 
were administered orally 22 hours after saline or LPS (0.5 mg/kg) administration. For Golgi 
staining, brain regions were collected 2 hours after administration of drugs.  (B-H): Golgi 
staining in the brain regions (PrL and IL regions of mPFC, core and shell of NAc, CA1, CA3, 
DG of hippocampus) was performed. Representative data of Golgi staining in the mouse brain 
regions. Data are shown as mean ± S.E.M. (n = 5 - 7). *P < 0.05, **P < 0.01, ***P < 0.001 
compared to vehicle-treated LPS group (one-way ANOVA, followed post hoc LSD test). N.S.: 
Not significant, Veh: Vehicle, Flu: Fluoxetine, Brex: Brexpiprazole 
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4. Discussion 
The major findings of this study are that combination of brexpiprazole and fluoxetine could 
promote a rapid antidepressant effect in an inflammation model of depression, although either 
drug alone did not show an antidepressant effect. Recently, we reported a rapid antidepressant 
effect of TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) in the same model (Zhang et al. 2015a), 
indicating that the rapid antidepressant effect of combination of brexpiprazole and fluoxetine 
is similar to 7,8-DHF’s rapid antidepressant action. To the best of our knowledge, this is the 
first report showing a rapid antidepressant effect for combination of brexpiprazole and 
fluoxetine in inflammation model of depression. Therefore, it is likely that adjunction of 
brexpiprazole to SSRI therapy could promote a rapid antidepressant effect in depressed patients.  
We previously reported a marked reduction of BDNF-TrkB signaling in the PFC, DG 
and CA3, but not CA1, of inflammation model of depression (Zhang et al. 2015a). A single 
systemic administration of 7,8-DHF promoted a rapid antidepressant effect in inflammation 
model of depression (Zhang et al. 2015a), implicating BDNF-TrkB signal pathway in the PFC, 
DG, and CA3 in the antidepressant action of TrkB agonist. This is consistent with decreased 
BDNF protein levels in the PFC, DG, CA3, but not CA1, in inflammation model (Zhang et al. 
2015a). In this study, we found that combination of brexpiprazole and fluoxetine could 
attenuate decreased BDNF-TrkB signaling in the PFC, CA3, and DG after inflammation. 
Therefore, it is possible that combination of brexpiprazole and fluoxetine might promote a 
rapid antidepressant effect by stimulation of BDNF-TrkB signaling in these regions. 
Several studies have shown that NAc plays a critical role in depression (Nestler and 
Carlezon 2006; Shirayama et al. 2015; Zhang et al. 2015a; 2015b; Yang et al. 2015a). We also 
reported that inflammation, social defeat stress and learned helplessness caused an increased 
BDNF-TrkB signaling within the NAc (Zhang et al. 2015a; 2015b; Shirayama et al. 2015; 
Yang et al. 2015a; 2015b). Taken together, this indicates that inflammation decreases BDNF 
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in the hippocampus and PFC, but increases BDNF in the NAc, resulting in depression-like 
behavior in rodents. Interestingly, we found that combination of brexpiprazole and fluoxetine 
attenuated the increase in the BDNF-TrkB signaling in NAc as well as PFC, and hippocampus.  
Further detailed studies examining the underlying mechanism of action for the combination of 
brexpiprazole and fluoxetine in the NAc are needed. 
Changes in dendritic length and spine density in the PFC and hippocampus are thought 
to contribute to the neurobiology of depression, and antidepressant treatment is mediated, in 
part, by blocking or reversing these changes (Duman and Aghajanian 2012; Ohgi et al. 2015; 
McEwen 2007). A single administration of TrkB agonist 7,8-DHF and TrkB antagonist ANA-
12 could normalize alterations in spine density in inflammation model by stimulation at TrkB 
in the PFC, CA3, and DG, as well as blockade of TrkB in the NAc, respectively (Zhang et al. 
2015a). Therefore, the combination of brexpiprazole and fluoxetine could act by normalizing 
altered dendritic spine density in all these regions, including PFC, hippocampus, and NAc. 
Thus, it seems that BDNF-TrkB signaling in NAc might play a role in the antidepressant effect 
of brexpiprazole plus fluoxetine, although further studies are needed. 
In conclusion, this study shows that adjunction of brexpiprazole to fluoxetine can 
produce a rapid antidepressant effect in inflammation model of depression. Therefore, it is 
likely that adjunction of brexpiprazole to SSRI could produce a rapid antidepressant effect in 
patients with major depression. 
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